Mirum Pharmaceuticals Inc MIRM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MIRM is a good fit for your portfolio.
News
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
-
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli
-
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Thinking about buying stock in Mirum Pharmaceuticals, Entera Bio, Andean Precious Metals, Viatris, or Biomx?
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Trading Information
- Previous Close Price
- $24.02
- Day Range
- $23.14–24.62
- 52-Week Range
- $23.14–35.56
- Bid/Ask
- $24.49 / $25.73
- Market Cap
- $1.15 Bil
- Volume/Avg
- 817,338 / 493,683
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.27
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 264
- Website
- https://www.mirumpharma.com
Comparables
Valuation
|
Metric
|
MIRM
|
PLRX
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.51 | 1.51 | 12.65 |
Price/Sales | 5.27 | 442.25 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
MIRM
PLRX
CBAY
Financial Strength
|
Metric
|
MIRM
|
PLRX
|
CBAY
|
|---|---|---|---|
Quick Ratio | 4.07 | 17.43 | 10.70 |
Current Ratio | 4.45 | 17.72 | 10.96 |
Interest Coverage | −10.66 | −145.34 | −5.27 |
Quick Ratio
MIRM
PLRX
CBAY
Profitability
|
Metric
|
MIRM
|
PLRX
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −19.13% | −22.68% | −30.06% |
Return on Equity (Normalized) | −52.80% | −24.50% | −51.97% |
Return on Invested Capital (Normalized) | −25.39% | −28.46% | −30.87% |
Return on Assets
MIRM
PLRX
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wxyxbrfgr | Skqr | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sjdxrwtf | Wnfzcjx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qnzwynx | Vvnsdj | $99.5 Bil | |
MRNA
| Moderna Inc | Hrnvzmbh | Lgffl | $38.8 Bil | |
ARGX
| argenx SE ADR | Kflcqdgp | Jsfl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hqqcxfz | Nqjxg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cfwtjyvds | Xqllhm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hhlhlxpgv | Krgtsv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cylhbwghss | Jsfws | $12.5 Bil | |
INCY
| Incyte Corp | Tfnzqcns | Zkgtmr | $11.6 Bil |